Zynerba Pharmaceuticals Inc: Best-Performing Cannabis Stock In First Half of 2019

2019年上半年表现最好的大麻股Zynerba:股票上涨355%,投资者对其持续看好

2019-07-12 08:30:00 PROFIT

本文共1775个字,阅读需5分钟

The first half of 2019 was very kind to the markets in general, with all of the major indices trading near or at record levels. And cannabis stocks continue to be one of the best plays. The top cannabis stock in the first half of 2019 isn’t one of the more common names you hear being discussed around the water cooler. Nevertheless, Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) saw its share price advance 355% in the first half of 2019, rising from a $2.98 open price on January 2 to a closing price of $13.55 on June 30. Zynerba is a clinical-stage specialty pharmaceutical company developing transdermal (under the skin) cannabinoid therapies to treat rare conditions. As a development-stage biotech company, earnings are not nearly as important as positive drug trials, patents, and approval from the Food and Drug Administration (FDA). Which is exactly what has been helping juice the Zynerba stock price. As just mentioned, Zynerba Pharmaceuticals Inc is a biotech firm that specializes in developing transdermal cannabinoid therapies that treat rare and near-rare conditions that affect the central nervous system and immune systems. Transdermal therapies are considered to be more efficacious than oral drugs because they are directly absorbed into the circulatory system, avoiding the gastrointestinal (GI) tract. That reduces the chance of GI-related problems. This method also allows for lower dosages and improved safety. Zynerba’s flagship product, which is still in the clinical development stage, is “Zygel,” a transdermal cannabidiol (CBD) gel that is used to treat Fragile X syndrome, Autism Spectrum Disorder (ASD), and rare epilepsy syndromes. Zygel is the lone pharmaceutically produced CBD gel being developed for transdermal delivery. In early May, Zynerba received “Fast Track” designation by the FDA for Zygel in the treatment of FXS. Fast Track designation helps biotech firms develop their drugs more quickly and speeds up the approval process. (Source: “Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS),” Zynerba Pharmaceuticals Inc, May 6, 2019.) The company expects the initial results from a study evaluating Zygel in children and adolescents with developmental and epileptic encephalopathies to be released in the third quarter of 2019 Top-line data from a study evaluating the safety and efficacy of Zygel for the treatment of children and adolescents with ASD is  expected in the first half of 2020. Data from a Phase 2 trial evaluating the safety and efficacy of Zygel for treating Deletion Syndrome is also expected  in the first half of 2020. In June, the company received a U.S. patent for treating ASD with Zygel. The new patent expires in 2038, although the company continues to look to expand its patent protection and find other market exclusive opportunities. ZYNE stock had great momentum in the first half of 2019, rising on the heels of investor optimism, Fast Track designation for Zygel, and a patent for treating ASD with Zygel. In fact, because the company isn’t reporting any revenue, all movement with ZYNE Pharmaceuticals stock is a result of encouraging developments associated with Zygel. That said, Zynerba stock could reverse just as quickly on poor test results. For now though, the future looks bright for this stock. Chart courtesy of StockCharts.com On May 8, Zynerba announced its financial results for the first quarter ended March 31, 2019. In the first quarter, the company announced a net loss of $9.1 million, or $0.47 per share, compared to a loss of $12.3 million, or $0.91 per share in the same prior-year period. Again, as a development-stage company, Zynerba is not generating any revenue. What’s most important is that it has enough cash to keep going. The company ended the first quarter with cash and cash equivalents of $68.3 million, compared to $59.8 million at the end of the fourth quarter of 2018. Management believes this cushion of cash is enough to fund operations and capital investments into the first quarter of 2021. This date goes beyond the potential approval of Zygel for the treatment of FXS. “We are entering a transformational period for Zynerba during which we expect top line data from four neuropsychiatric disorder trials with Zygel, our patent protected CBD gel,” said Armando Anido, Chairman and CEO. Anido added,Zynerba Pharmaceuticals Inc is a great small-cap biotech stock operating in the cannabis sector. Thanks to Fast Track designation from the FDA and a U.S. patent, Zynerba stock soared in the first six months of 2019. Just because the company’s share price shot up by an eye-watering 355% in the first half of 2019 does not mean it will replicate that feat in the second half. But the increased attention on the company and ongoing investor optimism bodes well for ZYNE stock as the company enrolls new patients in its clinical studies.
2019年上半年对市场总体来说是非常好的,所有主要股指都接近或处于创纪录水平。大麻库存仍然是最好的交易之一。 2019年上半年最大的大麻库存并不是你所听到的关于饮水机的讨论中最常见的名字之一。然而, Zyneba Pharmaceuticals Inc ( NASDAQ : ZYNE )的股价在2019年上半年上涨了355%,从1月2日2.98美元的公开价格上涨到6月30日13.55美元的收盘价。 Zyneba 是一家临床阶段的专业制药公司,致力于开发经皮(皮肤下)大麻素治疗罕见疾病的疗法。 作为一家处于发展阶段的生物技术公司,收益并不像积极的药物试验、专利和美国食品药品监督管理局(Food and Drug Administration)( FDA )的批准那么重要。这正是帮助推高 Zyneba 股价的原因所在。 正如刚才提到的, Zyneba Pharmaceuticals Inc 是一家生物技术公司,专门研发经皮大麻素治疗药物,治疗影响中枢神经系统和免疫系统的罕见和近乎罕见的疾病。 透皮疗法被认为比口服药物更有效,因为它们直接被吸收进入循环系统,避免胃肠道。这减少了与 GI 相关的问题的机会。这种方法还允许降低剂量和提高安全性。 Zyneba 的主打产品仍处于临床开发阶段,是“ Zygel ”,一种用于治疗 Fragile X 综合征、自闭症谱系障碍( ASD )和罕见的癫痫综合征的透皮大麻凝胶( CBD )。 Zygel 是正在开发用于透皮给药的唯一药物生产的 CBD 凝胶。 5月初, Zyneba 获得了 FDA 对 Zygel 治疗 FXS 的“快速通道”认证。快速跟踪指定帮助生物技术公司更快地开发他们的药物,并加快审批过程。 Zyneba 公司预计将于2019年第三季度发布一项评估儿童和青少年发育和癫痫脑病 Zygel 的研究的初步结果 一项评估 Zygel 治疗儿童和青少年自闭症的安全性和有效性的研究的一线数据预计在2020年上半年完成。 预计在2020年上半年,第二阶段试验的数据也将评估 Zygel 治疗删除综合征的安全性和有效性。 今年6月,该公司获得了 Zygel 治疗 ASD 的美国专利。新专利2038年到期,尽管公司继续寻求扩大专利保护,并寻找其他市场独家机会。(资料来源:“ Zyneba Pharmaceuticals , Inc .于2019年6月11日获得美国新专利,用于 Cannabiel 治疗自闭症谱系障碍。” ZYNE 股票在2019年上半年表现强劲,这得益于投资者的乐观情绪、 Zygel 的快速跟踪评级以及 Zygel 治疗 ASD 的专利。 事实上,由于公司没有报告任何收入, ZYNE 制药股票的所有变动都是与 Zygel 相关的令人鼓舞的发展的结果。 话虽如此, Zyneba 股价可能会在糟糕的测试结果下迅速逆转。不过现在看来,这只股票的前景是光明的。 5月8日, Zyneba 公布了截至2019年3月31日的第一季度财务业绩。 第一季度,该公司宣布净亏损910万美元,或每股亏损0.47美元,而上年同期亏损1230万美元,或每股亏损0.91美元。 同样,作为一家处于发展阶段的公司, Zyneba 没有产生任何收入。最重要的是,它有足够的现金来维持运营。公司第一季度末现金及现金等价物为6,830万美元,2018年第四季度末为5,980万美元。 管理层认为,这种现金缓冲足以为2021年第一季度的运营和资本投资提供资金。这个日期超出了 Zygel 治疗 FXS 的潜在批准。 “我们正进入 Zyneba 的转型时期,在此期间,我们预计 Zygel (我们的专利保护的 CBD 凝胶)四项神经精神疾病试验的顶级数据,”董事长兼首席执行官 Armando Anido 表示。 Anido 补充说,Zyneba Pharmaceuticals Inc 是一家在大麻领域运营的大型小型生物技术公司。 得益于 FDA 的快速通道和美国专利, Zyneba 的股票在2019年的前六个月飙升。 仅仅因为该公司股价在2019年上半年飙升355%,并不意味着它将在下半年复制这一壮举。但随着 ZYNE 将新患者纳入临床研究,该公司日益受到关注,投资者持续看好 ZYNE 股票。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文